International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 213-218
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Expression of PARP1 Gene in Breast Cancer Patients
Mustafa ULASLI1, Serdar GURSES2, Beyhan CENGIZ3, Serdar OZTUZCU1, Ozan BALAKAN4, Ali SUNER4, Bulent GOGEBAKAN5, Mehri IGCI1, Ahmet BALIK6, Ahmet ARSLAN1, Celalettin CAMCI4
1Gaziantep University Faculty of Medicine, Department of Medical Biology, Gaziantep, TURKEY
2Zirve University Emine Bahaeddin Nakıboğlu Faculty of Medicine, Department of Medical Biology, Gaziantep, TURKEY
3Gaziantep University Faculty of Medicine, Department of Physiology, Gaziantep, TURKEY
4Gaziantep University Faculty of Medicine, Department of Medical Oncology, Gaziantep, TURKEY
5Mustafa kemal University Faculty of Medicine Department of Medical Biology, Hatay, TURKEY
6Gaziantep University Faculty of Medicine, Department of General Surgery, Gaziantep, TURKEY
Keywords: Breast cancer, PARP1, Real time, qPCR
Poly (ADP-ribose) polymerase (PARP) family of enzymes is part of the DNA repair mechanism. One of these enzymes, PARP-1 is involved in detection of signal single-strand DNA breaks (SSBs) that leads to base excision repair (BER) mechanism. Breast cancer tumors that lack Breast cancer susceptibility gene 1 (BRCA1) and Breast cancer susceptibility gene 2 (BRCA2) are ineffective in DNA double-strand breaks (DSB) repair. Activity of the poly (ADP-ribose) polymerase (PARP) enzymes in these tumors is of interest as a lack of PARP activity leads to accumulation of SSBs that are converted to DSBs and accumulation of DSBs lead to irreparable DNA damage and cell death. Therefore inhibition of PARP in tumor cells might be effective in killing cancer tumors and activity of PARP inhibitors in selectively killing breast cancer tumors is currently being evaluated. In this study, expression of PARP-1 and cancer markers estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were determined in a group of breast cancer patients to assess the potential for using PARP inhibitors against this form of cancer. Expression of PARP- 1 was found not to correlate with the onset of breast cancer in the patients.
Mustafa ULASLI1, Serdar GURSES2, Beyhan CENGIZ3, Serdar OZTUZCU1, Ozan BALAKAN4, Ali SUNER4, Bulent GOGEBAKAN5, Mehri IGCI1, Ahmet BALIK6, Ahmet ARSLAN1, Celalettin CAMCI4
1Gaziantep University Faculty of Medicine, Department of Medical Biology, Gaziantep, TURKEY
2Zirve University Emine Bahaeddin Nakıboğlu Faculty of Medicine, Department of Medical Biology, Gaziantep, TURKEY
3Gaziantep University Faculty of Medicine, Department of Physiology, Gaziantep, TURKEY
4Gaziantep University Faculty of Medicine, Department of Medical Oncology, Gaziantep, TURKEY
5Mustafa kemal University Faculty of Medicine Department of Medical Biology, Hatay, TURKEY
6Gaziantep University Faculty of Medicine, Department of General Surgery, Gaziantep, TURKEY
Keywords: Breast cancer, PARP1, Real time, qPCR
Poly (ADP-ribose) polymerase (PARP) family of enzymes is part of the DNA repair mechanism. One of these enzymes, PARP-1 is involved in detection of signal single-strand DNA breaks (SSBs) that leads to base excision repair (BER) mechanism. Breast cancer tumors that lack Breast cancer susceptibility gene 1 (BRCA1) and Breast cancer susceptibility gene 2 (BRCA2) are ineffective in DNA double-strand breaks (DSB) repair. Activity of the poly (ADP-ribose) polymerase (PARP) enzymes in these tumors is of interest as a lack of PARP activity leads to accumulation of SSBs that are converted to DSBs and accumulation of DSBs lead to irreparable DNA damage and cell death. Therefore inhibition of PARP in tumor cells might be effective in killing cancer tumors and activity of PARP inhibitors in selectively killing breast cancer tumors is currently being evaluated. In this study, expression of PARP-1 and cancer markers estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were determined in a group of breast cancer patients to assess the potential for using PARP inhibitors against this form of cancer. Expression of PARP- 1 was found not to correlate with the onset of breast cancer in the patients.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |